Pfizer Prepares For Year-End US Bevacizumab Launch
Pfizer has cleared the way to launching its Zirabev bevacizumab biosimilar in the US on 31 December this year following a patent-litigation settlement with Roche.
You may also be interested in...
Pfizer is getting ready to ship its Zirabev biosimilar rival to Avastin in the US, at a price that represents a 23% discount to the brand and is also lower than the price for Amgen’s Mvasi biosimilar.
Samsung Bioepis has announced that its SB8 biosimilar bevacizumab candidate, a proposed US rival to Avastin, has been accepted for review by the FDA.
Amgen’s Mvasi and Kanjinti alternatives to Roche’s Avastin bevacizumab and Herceptin trastuzumab brands will from 1 October be preferred by plans administered by the largest US health insurer, UnitedHealthcare.